P-389 Phase 3, Two-stage, Randomized Trials of Mezigdomide-Based Regimens Versus Standard Regimens in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1 (mezivd Vs PVd) and SUCCESSOR-2 (mezikd Vs Kd)
Clinical Lymphoma Myeloma and Leukemia（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined